Nantkwest Inc (NASDAQ:NK)
The NANT Cancer Vaccine is the very first combination of an immunotherapy protocol to offer low radiation chemotherapy to activate the body’s adaptive and innate immune system as well as inducing immunogenic cell death. The vaccine seeks to achieve lasting sustainable remission of several types of tumor with low level of toxicity but increased level of efficacy compared to current standards.
NantKwest Inc. (NASDAQ:NK) Chairman and CEO, Patrick Soon-Shiong, said Abraxane was the first drug, derived from a protein, to change the survival rate for pancreatic cancer in over 20 years. He added that the company was not content with the mere approval of Abraxane as being a sufficient way to transform the disease. The company in 2016 launched the Cancer Breakthroughs 2020 roadmap. This effort is aimed at developing effective, customized cancer treatments using the body’s immune system as a paradigm change in cancer treatment. Shiong added that the approval by the FDA is a significant step in the company’s dream to develop the cancer vaccine which seeks to induce immunogenic cell death.
According to NantKwest Inc. (NASDAQ:NK) Senior Vice President of Clinical Development, John Lee, MD, FACS, the FDA approval for the IND application shows the company’s commitment to developing a novel immunotherapy approach. Lee says this is an important step in cancer treatments and strengthens the need for a change in the way doctors approach the disease. He added that NantKwest Inc. (NASDAQ:NK) and NantCell are leading the way in developing clinical studies in several investigational centers and a NANT Cancer Vaccine regimen could soon be available for pancreatic cancer patients.
NantKwest Inc. (NASDAQ:NK) Senior Vice President in charge of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology says that, in most cases, the immune system doesn’t detect cancer cells. He added that a recent study established cancer cells slow down the immune system using checkpoint receptors. With this revelation, a new immune-oncology revolution was initiated with launch of several checkpoint inhibitors
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.